Clinical Trial Update: Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 study evaluating adjunctive topiramate in infants aged 1–24 months for partial-onset seizures has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Topamax (Topiramate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Partial Seizure Disorder, Epilepsy | Phase 3 | Status: COMPLETED